Skip to main content
. 2021 Nov 3;11:754180. doi: 10.3389/fonc.2021.754180

Figure 2.

Figure 2

(A) OS of CD5+ DLBCL patients with the presence or absence of MYC, (B) with the presence or absence of BCL-2, and (C) with the presence or absence of BCL-6. (D) Coexpression of MYC/BCL-2; (E) coexpression of MYC/BCL-6; (F) COO subtypes.